Optilume BPH TURBO is the newest approved minimally invasive surgical therapy (MIST) for men with symptomatic BPH, backed by a pivotal trial with 5-year outcomes.
Recently approved by the U.S. Food and Drug Administration, Optilume BPH TURBO is a unique MIST that combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel for the treatment of LUTS secondary to BPH.
Mechanical dilation with Optilume BPH TURBO achieves an anterior commissurotomy, while delivery of paclitaxel is intended to maintain luminal patency during healing.
Optilume BPH TURBO is the first combination drug and device therapy offering the highest clinically reported flow rates of any minimal invasive therapy with immediate and sustained improvement in IPSS symptom scores.
The recent FDA approval and published positive data will quickly establish Optilume BPH TURBO as a new standard for physicians and men looking for rapid and sustained results in treating LUTS caused by BPH.
Optilume BPH TURBO is a minimally invasive treatment option for men with BPH or lower urinary tract symptoms who want to avoid surgery or medications.
Key Benefits of the Optilume BPH TURBO Treatment System:
Find your BPH symptom score.
Consult with our world-class medical experts within days of your call.
The Optilume BPH TURBO prostate procedure involves inserting a medication-coated balloon (1 of 4 different sizes based on the prostate size and length) into the prostate urethral space, which gently reshapes the anterior prostatic urethra to create a wider passage, known as an anterior commissurotomy (crack in the upper portion of the prostate), in just 10 minutes.
The principle is to increase the height of the prostatic urethra – similar to opening the zipper on a suitcase, allowing a significant reduction in resistance to urinary flow.
The Optilume BPH TURBO procedure is performed in-office with light sedation and local anesthesia.
Firstly, the patient lies on their back with their legs in stirrups. The catheter is then inserted into the urethra up to the location of the prostate.
Once the catheter is set in place, a cylindrical balloon is inflated to press against the prostate tissue, creating a passageway for urine to flow through. As the balloon expands, it creates micro fissures in the tissue.
The coating of the balloon releases a therapeutic medication directly onto the fissured tissue. This medication reduces cell proliferation and fibrotic scar tissue generation, which helps relieve urinary obstruction and improves the flow of urine.
The procedure is a quick in-office solution, performed in under 30 minutes.
The Optilume BPH TURBO prostate procedure has a quick catheter removal, improved urinary flow improvements and quick recovery. Patients may resume their normal activities within a few days following the procedure.
Effective BPH symptom relief with minimally invasive and low risk treatments.
“Optilume BPH TURBO will revolutionize prostate office-based outpatient treatment with unparalleled urinary flow rate outcome improvements. This will dramatically change the patient recovery journey. I foresee this simple procedure and medicated balloon dilation becoming the new leader of outpatient MIST prostate BPH therapies.”
Optilume BPH is the newest approved minimally invasive surgical therapy (MIST) for men with symptomatic BPH, backed by a pivotal trial with 5-year outcomes. Unlike other MISTS, such as REZUM (which rely on heat/steam to burn tissue requiring catheter two weeks), iTIND (temporary nitinol metal implant for one week with pressure incisions) and Urolift (permanent metallic implants to compress BPH tissue), the Optilume BPH system is unique and completely different in speed of results, short catheterization (only two days), faster recovery (under 2-3 weeks) and no foreign implants.
In July 2024, Dr. Kevin Zorn and the BPH Canada team in Montreal performed the world's first office-based Optilume BPH procedure under local anesthesia. This milestone highlights the treatment’s potential for accessibility, offering a quick, in-office solution (under 30 minutes) to help men transition off long-term BPH medications, which often have sexual side effects and health risks.
The treatment involves the deployment of a medication-coated balloon at the level of the prostate, which reshapes the prostatic urethral with a taller passage (what is referred to as an anterior commissurotomy) for only 10 minutes. Similar to cardiac angioplasty and the immediate impact of reopening obstructed heart vascular flow, the Optilume rapidly restores urinary flow and has the shortest catheterization times and fastest recovery time.
Under Dr. Zorn's care, all 15 cases have had successful balloon dilation delivered in under 30 minutes with no complications.
Similar to any medical procedure, there are some potential risks and side effects associated with Optilume BPH TURBO.
However, they are typically very low in comparison to its benefits.
It is possible for some patients to experience discomfort or pain during the procedure, particularly if the catheter is inflated too tightly. Patients may also experience bleeding or bruising in the urethra or the surrounding tissue, which typically resolves on its own. In rare cases, urinary tract infections (UTI) following the procedure may occur.
The Optilume medication is an antiproliferative drug that coats the balloon in order to stop urethral strictures from forming. It does this by minimizing the overactivity of cells and the formation of scar tissue.
Compared to REZUM therapy, men must wear their catheter for 2-3 weeks and only see urinary flow improvements at 4-6 weeks taking up to 3 months to get maximal healing. With Optilume BPH, patients see the results immediately at the catheter removal on Day 2.
Patients generally experience only mild to moderate discomfort during the part of the procedure when the balloon is expanded in the urethra. Other than that, the procedure is typically painless.
Only one treatment of Optilume BPH TURBO is required to achieve urinary symptom relief.
AR
HY
ZH-CN
EN
DE
EL
IT
FA
PT
ES
TR
JP
